Background: Older patients with type 2 diabetes mellitus (T2DM) are often undertreated because of concerns regarding hypoglycaemia and clinical heterogeneity. Although the evidence base for oral semaglutide is growing, data specifically in older adults remain relatively limited, particularly regarding long-term effectiveness and tolerability in routine practice. Methods: This observational study included 81 patients aged ≥65 years with T2DM treated with oral semaglutide for 12 months. Changes in glycaemic, anthropometric and cardiometabolic parameters were evaluated. The primary endpoint was the achievement of HbA1c < 7% at 12 months. Multivariable logistic regression was performed to identify baseline predictors of response. Results: HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001). Significant reductions were observed in body weight (−4.09 ± 4.42 kg, p < 0.00001), BMI (−1.50 ± 1.55 kg/m2, p < 0.00001) and waist circumference (−5.83 ± 4.71 cm, p < 0.00001). Improvements were also detected in lipid profile, blood pressure and visceral adiposity indices. No hypoglycaemic events were reported during follow-up. In multivariable analysis, baseline age, diabetes duration, baseline HbA1c and baseline VAI were not independently associated with the achievement of HbA1c < 7%; therefore, these baseline factors did not discriminate responders within our cohort (hypothesis-generating). Greater absolute HbA1c reductions were observed in patients with higher baseline HbA1c. Conclusions: In older patients with T2DM, oral semaglutide is associated with effective glycaemic control without hypoglycaemia and with a response largely independent of baseline clinical characteristics, supporting its use in elderly and clinically heterogeneous populations.
PCSK9 inhibition reduces cardiovascular events in patients with type 2 diabetes, while experimental studies implicate PCSK9 in immune activation, platelet function and organ-specific metabolism. Whether these mechanisms contribute clinically beyond atherogenic lipoprotein lowering remains uncertain. This critical narrative review integrates 108 appraised publications identified through structured searches and supplementary retrieval. Mechanistic evidence supports roles involving LDLR, CD36, intracellular cholesterol, mitochondrial stress and inflammatory signalling. The effects vary by cell type and compartment: local PCSK9 can promote injury in some models but preserve pancreatic, glomerular or cardiac function in others. Global knockout, tissue-specific deletion, extracellular antibodies and hepatic silencing consequently cannot be treated as equivalent interventions. Human biomarker and imaging studies provide translational signals, but generally cannot separate direct effects from concomitant lipoprotein changes. Randomised antibody trials establish cardiovascular efficacy and an overall reassuring glycaemic profile during follow-up, without demonstrating a clinically meaningful glucose-lowering effect. PCSK9 therefore has immunometabolic functions beyond plasma LDL regulation, but the available evidence does not isolate or quantify an additional clinical benefit independent of reductions in atherogenic lipoproteins. Tissue-specific mechanisms and causal mediation require further investigation before broader therapeutic claims are justified.
Background: Longitudinal changes in estimated cardiovascular risk vary across indi-viduals with type 2 diabetes. We investigated whether baseline clinical data predict a relative decrease of at least 10% in the DIAL2-derived calibrated one-year cardiovascular risk estimate (P1Y) over two years. Methods: This single-centre observational prediction analysis used data collected at ASST Mantova. Of 332 source records, 324 had valid P1Y estimates at baseline (T0) and two years (T2). Elastic net logistic regression and random forest were assessed with three repetitions of nested stratified five-fold cross-validation. We assessed discrimination, average precision, Brier score, and calibration of held-out predictions. Results: The response criterion was met in 135 of 324 patients (41.7%). Mean test-fold area under the receiver operating characteristic curve (AUROC) was 0.788 (fold SD 0.043) with elastic net and 0.780 (0.047) with random forest. Average precision was 0.755 and 0.740, and Brier score was 0.183 and 0.190. Elastic net without treatment group yielded AUROC 0.783. Averaged held-out elastic net predictions had AUROC 0.792 and calibration slope 0.978. At fixed baseline age, 230/324 (71.0%) met the reduction criterion; a separately validated elastic net had mean AUROC 0.751. Outcomes were changes in a computed risk estimate, not observed cardiovascular events. Conclusions: Baseline characteristics discriminated individuals with a two-year reduction in estimated annual risk in internal validation. Endpoint status was sensitive to the age term in DIAL2. These findings require validation in an independent cohort; model outputs cannot establish the effect of any therapy on clinical cardiovascular outcomes.
Background: Older patients with type 2 diabetes mellitus (T2DM) are often undertreated because of concerns regarding hypoglycaemia and clinical heterogeneity. Data on the effectiveness of oral semaglutide in this population remain limited. Methods: This observational study included 81 patients aged ≥65 years with T2DM treated with oral semaglutide for 12 months. Changes in glycaemic, anthropometric and cardiometabolic parameters were evaluated. The primary endpoint was achievement of HbA1c <7% at 12 months. Multivariable logistic regression was performed to identify baseline predictors of response. Results: HbA1c decreased from 7.75 ± 1.01% to 6.80 ± 0.88% after 12 months (p < 0.00001). Significant reductions were observed in body weight (−4.09 ± 4.42 kg, p < 0.00001), BMI (−1.50 ± 1.55 kg/m², p < 0.00001) and waist circumference (−5.83 ± 4.71 cm, p < 0.00001). Improvements were also detected in lipid profile, blood pressure and visceral adiposity indices. No hypoglycaemic events were reported during follow-up. In multivariable analysis, no baseline clinical or metabolic variable independently predicted achievement of HbA1c <7%, indicating a homogeneous glycaemic response across the study population. Greater absolute HbA1c reductions were observed in patients with higher baseline HbA1c. Conclusions: In older patients with T2DM, oral semaglutide is associated with effective glycaemic control without hypoglycaemia and with a response largely independent of baseline clinical characteristics, supporting its use in elderly and clinically heterogeneous populations.
Background/Objectives: Orforglipron and danuglipron are the two most clinically advanced oral small-molecule (non-peptide) GLP-1 receptor agonists, sharing a common mechanism of action but markedly different regulatory outcomes — approval versus discontinuation. No existing review synthesizes their complete registrational evidence. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science (inception to September 2026; PROSPERO-registered protocol) for phase 2/3 randomized controlled trials of orforglipron or danuglipron in adults with type 2 diabetes and/or obesity. Risk of bias was assessed with Cochrane RoB 2. Comparable trials were pooled using random-effects meta-analysis; clinically heterogeneous or non-comparable trials were synthesized narratively. Results: Of 505 records identified (286 after deduplication), 13 phase 2/3 randomized controlled trials met the registered eligibility criteria (10 orforglipron, 3 danuglipron); a further 17 reports (phase 1, mechanistic, or post hoc analyses of these trials) were retained only as contextual evidence. Of the 13 eligible trials, 9 (6 orforglipron phase 3, 3 danuglipron phase 2; N=9,693) were included in the quantitative synthesis, of which subsets sharing a common comparator were combined by random-effects meta-analysis (3 trials for HbA1c, 2 for body weight in type 2 diabetes); the remainder are reported as standalone estimates. Orforglipron produced a pooled HbA1c reduction of −1.14 percentage points versus placebo (95% CI −1.25 to −1.02; I²=0%) and superior glycemic control versus dapagliflozin and oral semaglutide. Weight loss varied by population: −9.10% in obesity without diabetes (single trial) and a pooled −6.54% in type 2 diabetes (95% CI −7.96 to −5.11; I²=49.8%, explained by background therapy). No hepatic safety signal was observed across 11,220 pooled orforglipron participants. Danuglipron showed comparable glycemic and weight efficacy but substantially higher, dose-dependent discontinuation (up to 72.7% in one arm), and its development was discontinued after a probable drug-induced liver injury case identified in a later, unpublished study. Conclusions: Despite a shared molecular target, orforglipron and danuglipron followed divergent clinical trajectories driven by differences in dosing regimen, tolerability, and hepatic safety rather than by pharmacodynamic efficacy, which was broadly comparable between the two molecules. These findings underscore that efficacy alone is an incomplete predictor of clinical success for oral small-molecule GLP-1 receptor agonists.
Background: Oral semaglutide produces substantial average weight loss, but the term non-responder combines clinically different situations. Failure to cross a numerical threshold may reflect limited treatment exposure, intolerance, a slow trajectory or persistently inadequate efficacy. Identifying these situations is particularly important when evidence from diabetes doses is applied to oral obesity treatment. Objective: To critically examine definitions of inadequate weight response to oral semaglutide and assess whether baseline characteristics or early treatment patterns identify patients likely to derive less weight benefit. Methods: A narrative synthesis drew on searches of PubMed, Embase, Web of Science and CENTRAL, supplemented by primary trial appendices and conference materials. Evidence was interpreted separately by oral dose, diabetes status, follow-up, analysis population and publication type. Observed responder counts were distinguished from model-based estimates. No quantitative pooling was performed. Results: The apparent frequency of weight loss below 5% varied substantially with population, dose and denominator. At the end of OASIS 4, 40/192 participants with observed in-trial measurements and 20/157 with on-treatment measurements remained below 5% loss. These proportions do not establish biological resistance. Baseline sex and body weight showed exploratory signals in OASIS 1, whereas age, BMI, diabetes duration and baseline HbA1c did not consistently distinguish weight response across studies. An OASIS 4 post hoc analysis associated early weight loss with subsequent trajectories, but participants below 5% loss at week 16 still achieved a mean 7.0% reduction at week 64. Behavioral and exposure models remain exploratory. Conclusions: Current evidence supports a time-dependent, treatment-specific assessment of inadequate weight response rather than a fixed baseline non-responder phenotype. Early trajectories inform expectations but do not validate an automatic stopping rule. Persistent low weight response should be described alongside achieved dose, administration, persistence, tolerability and other treatment outcomes.